Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anirban Goutam Mukherjee has a total of 173 co-authors. Here are the top co-authors by number of shared publications:

  • Abilash Valsala Gopalakrishnan

    Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, India

    57 shared publications
  • Uddesh Ramesh Wanjari

    Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India

    27 shared publications
  • Kaviyarasi Renu

    Centre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College & Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

    24 shared publications
  • Balachandar Vellingiri

    Stem cell and Regenerative Medicine/Translational Research, Department of Zoology, School of Basic Sciences, Central University of Punjab (CUPB), Bathinda - 151401, Punjab, India

    23 shared publications
  • Balachandar Vellingiri

    Neurobiology (Ageing & Pediatric) Laboratory [NAP Lab], Department of Zoology Central University of Punjab Bathinda Punjab India

    20 shared publications
  • Raja Ganesan

    Department of Biotechnology, Faculty of Science and Humanities SRM Institute of Science and Technology Kattankulathur, Chengalpattu Tamil Nadu India

    18 shared publications

Latest Publications

  • Next-generation anti-obesity drugs: emerging molecular targets and translational opportunities

    by Sneha Shetty, Asmi Rangle, Anirban Goutam Mukherjee, Ankit Kumar Bharti, Sudip Prasad Jena, Sabina Evan Prince, Abilash Valsala Gopalakrishnan

  • Convergence of IoT-enabled biosensors and intelligent packaging for real-time food safety

    by Suryapratap Ray, Labhini Lalit Rahangdale, Anirban Goutam Mukherjee

  • Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming

    by Anirban Goutam Mukherjee, Ankit Kumar Bharti, Deepthi Maria Mathew, Abilash Valsala Gopalakrishnan, S. Nishu

  • RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting

    by Anirban Goutam Mukherjee, Ankit Kumar Bharti, Deepthi Maria Mathew, Bhavani Manoj Varma, Sristy Pradhan, Abilash Valsala Gopalakrishnan

    Epitranscriptomics has rapidly evolved into a central layer of post-transcriptional gene regulation in cancer, yet its mechanistic contribution to regulated cell death remains incompletely resolved. This review critically examines how RNA modifications principally N⁶-methyladenosine (m⁶A), alongside 5-methylcytosine (m5C), N⁷-methylguanosine (m⁷G), pseudouridylation (Ψ), and adenosine-to-inosine (A-to-I) editing reprogram apoptotic and ferroptotic thresholds in malignant cells. It highlights that m⁶A does not exert uniform effects; rather, outcomes are dictated by site specificity, reader stoichiometry, and cellular context, with opposing roles observed in the regulation of BCL-2 family signaling and the SLC7A11-GPX4 antioxidant axis. The analysis extends beyond m⁶A to evaluate emerging, yet often under-validated, evidence implicating m5C in ferroptosis resistance, A-to-I editing in immune evasion, and m⁷G/Ψ in translational control of survival programs. Importantly, the review integrates tumor microenvironmental pressures including hypoxia, reactive oxygen species, and immune signaling-as dynamic modulators of epitranscriptomic machinery, thereby linking RNA chemistry to adaptive stress responses and therapeutic resistance. Despite rapid technological advances, including MeRIP-seq, crosslinking-based mapping, and nanopore direct RNA sequencing, the field remains constrained by limited resolution, lack of quantitative stoichiometry, and insufficient site-specific functional validation. Many conclusions are derived from global perturbation of epitranscriptomic enzymes, obscuring causal attribution to individual modified transcripts. From a translational perspective, targeting writers, erasers, and readers offers promise for sensitizing tumors to cell death; however, pleiotropy, context dependency, and potential toxicity present significant barriers. Overall, this review argues that while epitranscriptomics represents a compelling regulatory axis in cancer cell death, advancing the field will require integrative, high-resolution, and functionally precise approaches to move beyond correlative frameworks toward mechanistic and clinically actionable insights.

  • Microbiome‐Derived Metabolite Networks in Metabolic Dysfunction‐Associated Fatty Liver Disease: Mechanistic Integration of Gut‐Liver Axis Signaling and Therapeutic Targeting

    by Adhiyaman Muniraj, Shreshta Vidhya Elango, Mahalaxmi Iyer, Mederametla Roja Rani, Saranya Vinayagam, Lalitha Gnanasekaran, Mukesh Kumar Yadav, Krothapalli Raja Surya Sambasiva Rao, Balachandar Vellingiri, Anirban Goutam Mukherjee, et al.

    Metabolic dysfunction‐associated fatty liver disease (MAFLD), recently reclassified within the broader framework of metabolic dysfunction‐associated steatotic liver disease (MASLD), has emerged as one of the leading causes of chronic liver disease. Although a substantial proportion of the mechanistic literature was originally generated under the non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) nomenclature, increasing evidence implicates the gut microbiome and its metabolic products as important contributors to disease pathogenesis. However, current understanding remains limited by fragmented analyses of individual pathways and an incomplete integration of microbial metabolism with host signaling networks. This review critically synthesizes the roles of microbiome‐associated metabolites and microbial products within the gut‐liver axis, with particular emphasis on bile acid signaling, short‐chain fatty acid (SCFA) metabolism, and tryptophan‐derived pathways, including kynurenine, indole, and serotonin metabolism. These pathways are discussed within an integrated mechanistic framework involving farnesoid X receptor (FXR)/TGR5, AMP‐activated protein kinase (AMPK), aryl hydrocarbon receptor (AhR), nuclear factor kappa B (NF‐κB), and inflammasome signaling. Particular attention is given to the context‐dependent effects of bile acids and SCFAs, the complex immunometabolic functions of the kynurenine pathway, and the interplay between microbial metabolites and innate immune activation. Future therapeutic strategies will likely combine microbiome‐directed approaches, including dietary interventions and microbiome modulation, with metabolite‐targeted and pathway‐specific interventions designed to improve mechanistic precision and therapeutic efficacy. This review aims to provide an integrated perspective on microbiome‐metabolite‐host interactions and highlights future opportunities for biomarker discovery, therapeutic development, and precision medicine in MAFLD.

  • Mechanobiology‐Driven Metabolic Reprogramming: Integrative Roles of YAP/TAZ Signaling and Extracellular Matrix Dynamics

    by Arul Narayanasamy, Panimalar Abirami Karuppusamy, Roselin Gnanarajan, Nandita Ravichandran, Deenathayalan Uvarajan, Mahalaxmi Iyer, Jayalakshmi Krishnan, Jyoti Parkash, Dibbanti Harikrishnareddy, Adhiyaman Muniraj, et al.

    Mechanobiology has emerged as a critical regulator of cellular metabolism, linking physical forces to transcriptional, metabolic, and epigenetic adaptations across multiple organ systems. However, the mechanisms by which extracellular matrix (ECM) dynamics and mechanotransduction pathways coordinate metabolic reprogramming in physiological and pathological conditions remain incompletely understood. This review provides a focused mechanometabolic framework integrating cardiovascular, skeletal, and endocrine systems through the convergence of ECM remodeling, cytoskeletal tension, and force‐dependent signaling pathways. Central to this framework is the YAP/TAZ signaling axis, which functions as a mechanosensitive transcriptional regulator downstream of integrin‐focal adhesion kinase (FAK)‐Src, RhoA/ROCK, actomyosin tension, and Hippo‐dependent and Hippo‐independent signaling networks. These pathways regulate metabolic programs involving glycolysis, mitochondrial function, redox homeostasis, and anabolic biosynthesis through downstream targets including GLUT1, HK2, PFKFB3, and mitochondrial regulatory pathways. The review critically examines how aberrant mechanotransduction contributes to cardiovascular remodeling, endothelial dysfunction, fibrosis, and metabolic disease progression, while also discussing the context‐dependent roles of YAP/TAZ signaling in adaptive versus pathological responses. In skeletal metabolism, the gut‐bone axis is presented as a bidirectional mechanochemical network in which microbiota‐derived metabolites, osteoimmune signaling, and biomechanical loading coordinately regulate bone remodeling and systemic metabolism. Furthermore, the review evaluates emerging evidence linking viscoelasticity, mitochondrial dynamics, and immunometabolism to disease progression and therapeutic responsiveness. Advances in mechanobiomaterials and regenerative strategies are also discussed, emphasizing their ability to modulate cellular energetics and mechanotransduction pathways to restore tissue homeostasis. Finally, current limitations in mechanobiology research, including model heterogeneity, tissue‐specific mechanical responses, and translational barriers, are highlighted. Collectively, this review establishes mechanobiology as a systems‐level regulator of metabolic reprogramming and underscores the therapeutic potential of targeting mechanometabolic pathways in human disease.


  • Top Cited Papers

    Harmful algal blooms in a changing world: linking bloom dynamics, biotoxin synthesis, and advanced monitoring strategies

    by Gracy Anu Francis, Suryapratap Ray, Anirban Goutam Mukherjee, Abilash Valsala Gopalakrishnan, Rahul Vashishth

    Harmful algal blooms (HABs) constitute an increasingly severe global ecological and public health threat, driven primarily by anthropogenic nutrient enrichment, coastal pollution, and climate-induced environmental change. Intensifying eutrophication, ocean warming, and hydrological variability have increased bloom frequency, geographic expansion, and toxin production, resulting in profound disruptions to marine food webs. HAB-forming microalgae and cyanobacteria synthesize a diverse array of potent biotoxins that alter zooplankton dynamics, cause extensive fish and marine wildlife mortalities, and pose significant risks to human health through contaminated seafood and water supplies. This review critically examines the principal taxa responsible for HAB events, integrating ecological, genetic, and environmental determinants that regulate bloom development and biotoxin biosynthesis. Major classes of algal biotoxins, their mechanisms of action, and their cascading impacts on marine ecosystems and public health are systematically evaluated. In addition, recent advances in HAB and toxin detection technologies, including molecular, biochemical, and remote sensing approaches, are synthesized alongside current management and mitigation strategies. By linking bloom-driving conditions, toxicity indicators, and monitoring frameworks, this review provides an integrated foundation for strengthening early-warning systems, risk assessment, and adaptive response strategies. Overall, the synthesis highlights emerging technologies and research priorities critical for mitigating the ecological and societal impacts of this escalating environmental crisis.


  • Biomedical and Therapeutic Insights into Titanium Dioxide and Palladium Nanoparticles: Recent Advances and Future Perspectives

    by Sathiya Nathan S, Kaviyarasi Renu, Anirban Goutam Mukherjee, M. Manivannan, R. Amutha